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Summary
Children with systemic Juvenile Idiopathic Arthritis (sJIA), the most
severe subtype of JIA, are at risk from destructive polyarthritis and
growth failure, and corticosteroids as part of conventional treatment can
result in osteoporosis and growth delay. In children where there is failure
or toxicity from drug therapies, disease has been successfully controlled
by T-cell-depleted autologous stem cell transplantation (ASCT). At pres-
ent, the immunological basis underlying remission after ASCT is
unknown. Immune reconstitution of T cells, B cells, natural killer cells,
natural killer T cells and monocytes, in parallel with T-cell receptor
(TCR) diversity by analysis of the b variable region (TCRVb) complemen-
tarity determining region-3 (CDR3) using spectratyping and sequencing,
were studied in five children with sJIA before and after ASCT. At time of
follow up (mean 115 years), four patients remain in complete remission,
while one child relapsed within 1 month of transplant. The CD8+ TCRVb
repertoire was highly oligoclonal early in immune reconstitution and re-
emergence of pre-transplant TCRVb CDR3 dominant peaks was observed
after transplant in certain TCRVb families. Further, re-emergence of pre-
ASCT clonal sequences in addition to new sequences was identified after
transplant. These results suggest that a chimeric TCR repertoire, compris-
ing T-cell clones developed before and after transplant, can be associated
with clinical remission from severe arthritis.
Keywords: autologous stem cell transplantation; childhood arthritis;
immune reconstitution; T-cell receptor repertoire clonal diversity.
Introduction
Juvenile idiopathic arthritis (JIA) is a common childhood
autoimmune disease, and encompasses a heterogeneous
group of disorders classified according to clinical features
observed during the first 6 months of disease.1 Systemic
JIA (sJIA), still currently classified as a subtype of JIA, is
characterized by arthritis, quotidian fever, erythematous
rash, lymphadenopathy, hepatosplenomegaly and serositis
and has a risk of associated mortality if not well
controlled.2 However, given its features of systemic
inflammation, sJIA is now considered to be more similar
to an autoinflammatory disorder and may be considered
to have separate pathogenesis from other JIA subtypes.3
Despite significant advances in the treatment of sJIA,
there remain children who suffer from active disease that
is refractory to novel anti-rheumatic drugs. These chil-
dren can endure considerable complications secondary to
chronic inflammation and cumulative drug toxicity,
including joint erosions, osteoporosis and growth failure.4
Abbreviations: ASCT, autologous stem cell transplantation; TCRVb, T-cell receptor diversity by analysis of b variable region;
CDR3, complementarity determining region-3; sJIA, systemic juvenile idiopathic arthritis
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A number of children with very severe and refractory
disease have been successfully treated by autologous stem
cell transplantation (ASCT).5–9 Those who achieve drug-
free remission after transplant benefit significantly from a
catch up of growth and experience a considerable
improvement in psychosocial morbidity and quality of
life.
However, although outcomes can be highly successful,
the risks associated with ASCT are also significant: intense
immunosuppression and prolonged T-cell lymphopenia
can lead to serious infection and exacerbation of macro-
phage activation syndrome, and these complications are
associated with a high mortality.5,7,10 Therefore, it is cru-
cial that only children who are least expected to suffer
from complications and have a good prospect of remis-
sion from disease are identified for transplantation.
A number of other autoimmune disorders, including
multiple sclerosis (MS), rheumatoid arthritis and systemic
lupus erythematosus, have also been managed successfully
by ASCT.11–14 However, despite encouraging results, simi-
lar to those challenges faced in sJIA, stem cell mobiliza-
tion, immune ablation and stem cell infusion in some
patients are associated with multiple adverse events,
including hepatic toxicity, cardiac failure and infection.
Furthermore, the response to ASCT varies considerably
between patients and it is challenging to determine which
patients will have disease remission. Interestingly, it has
been observed that younger patients suffering from MS
had significantly higher remission probabilities in com-
parison to older patients.11
It has been suggested that high-dose immunosuppres-
sion administered as part of the ASCT protocol might
contribute towards the elimination of autoreactive lym-
phocytes mediating the pathological autoimmune
response.15,16 However, to date, the immunological basis
of remission is poorly understood. Numerous studies
investigating ASCT for the management of severe auto-
immune diseases report that remission is associated
with a marked expansion of recent thymic emigrants
and the emergence of a new and more diverse T-cell
receptor (TCR) repertoire, consistent with the genera-
tion of a ‘new’ T-cell compartment of the immune
system.17,18
However, one recent study investigating ASCT in MS
identified the re-emergence of autoreactive T cells, by
expanding T cells on known antigens, in the context of
remission. It was suggested that these antigens might have
played a role in pathology before transplant.19 Another
study exploring immune reconstitution in JIA showed an
increased regulatory activity in autoreactive T-cell clones
post transplant.6 Furthermore, a preferential reconstitu-
tion of CD4+ CD25bright T regulatory cells in the thymus
was observed. Together, these might suggest that induc-
tion of self-tolerance and remission from disease could be
achieved through the ‘resetting’ of immune balance.
Of note, a predominance of CD45RO+ memory T cells
is observed very early post transplant in the treatment of
various autoimmune and malignant conditions.7,17,20–22 It
is yet to be confirmed whether this can be attributed to
the persistence of pre-primed, pre-transplant T cells with
greater capacity for expansion compared with de novo
generated cells, acquisition of CD45RO expression by rap-
idly proliferating naive T cells, or both.
To further understand the immunological mechanisms
underlying remission from sJIA after ASCT, in this study
we investigated the immune reconstitution and T-cell
repertoire of children with sJIA undergoing transplanta-
tion. Results indicate that remission from severe arthritis
can be associated with an immune system comprising of
re-emerging T-cell clones that were previously identified
before transplant as well as de novo generated clones. In
addition, preliminary data from one patient who relapsed
shortly post transplant suggest that the presence of full-
length TCR complementarity determining region-3
(CDR3) diversity early during immune reconstitution
might be associated with an inadequate conditioning regi-
men, inadequate immune depletion and relapse of dis-
ease.
These results, together with past and future studies,
may help to elucidate which patients are most likely to
benefit from ASCT, and may help to determine optimal
conditioning regimens for induction of remission while
minimizing risks associated with intense immunosuppres-
sive therapy.
Materials and methods
Patient samples and cell preparation
Peripheral venous blood samples were obtained from five
children with sJIA before, 1 month, 3–12 months and
2–3 years after ASCT, with fully informed parental con-
sent and age appropriate child assent. The study had full
ethical approval. Peripheral blood mononuclear cells were
prepared by density gradient centrifugation using LYMPHO-
PREP (Axis-Shield, Dundee, UK).
Immunophenotypic analysis
Peripheral blood mononuclear cells were assessed for
expression of T-cell, B-cell, natural killer (NK) cell, NK-
T-cell and monocyte surface markers by flow cytometry
[CD3, CD19, CD16, CD14, CD4, CD8, CD45RA and
CD45RO, using the following fluorochromes: FITC, phy-
coerythrin, PC7, allophycocyanin, Peridinin chlorophyll
protein-Cy5.5, Qdot605, allophycocyanin-Cy7 and V450,
purchased from: BD (Franklin Lakes, NJ), Life Technolo-
gies (Carlsbad, CA), eBioscience (San Diego, CA) or
Beckman Coulter (Brea, CA)]. TCRVb staining was per-
formed using the IOTEST Beta Mark Kit (Beckman
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Coulter) according to the manufacturer’s instructions.
LIVE/DEAD Fixable blue Dead Cell Stain (Life Technolo-
gies) was used to exclude dead cells. Cytometric analysis
was performed using LSRII or FACScan (both BD) and
FLOWJO (Treestar Inc., Ashland, OR).
TCR repertoire analysis
CD4+ and CD8+ T-cell populations were separated using
CD4+-positive selection magnetic bead sorting (Miltenyi
Biotec, Bergisch Gladbach, Germany) and the CD4 frac-
tion was used as the source of CD8+ T cells. Sort purity
for CD4+ sorted cells was typically ≥ 90%. Messenger
RNA was extracted from sorted cells using RNAzol
(Biogenesis, Westminster, CO) and cDNA was synthesized
using SuperScript reverse transcriptase and Oligo-dT
(both Life Technologies). The TCR b variable regions
(TCRVb) were amplified from cDNA using Vb family
primers (see Supporting information, Table S1). The fol-
lowing cycling conditions were used: 95° for 25 seconds,
35 cycles of 95° for 25 seconds, 60° for 45 seconds, 72°
for 45 seconds, then 72° for 5 min.
For TCRVb CDR3 spectratyping, PCR products from
each TCRVb were used in primer-extension reactions
with 5′ FAM-labelled Vb primer (Table S1). The follow-
ing cycling conditions were used: 95° for 25 seconds, 40
cycles of 95° for 25 seconds, 60° for 45 seconds and 72°
for 45 seconds, then 72° for 5 min. Spectrayping was per-
formed on an AB3130 Genetic Analyzer (Applied Biosys-
tems, Carlsbad, CA).
For TCRVb sequencing, PCR products from each
TCRVb were cloned using a TOPO kit (Life Technolo-
gies). Between 16 and 25 clones per TCRVb family per
time-point were amplified using M13 primers (Table S1).
The following cycling conditions were used: 94° for
5 min, 30 cycles of 94° for 30 seconds, 55° for 30 seconds
and 72° for 45 seconds, then 72° for 5 min. Sequencing
was performed on a 3730xl capillary sequencer (UCL
Genomics, London, UK).
Results
Patient clinical features and outcomes of ASCT
To study immune reconstitution after ASCT, peripheral
venous blood was obtained from five children with sJIA
before and at several time-points after transplant. Clinical
features and outcomes for these patients are summarized
in Table 1. We have previously reported on the clinical
details of transplant and early follow up, for these
patients:5 longer-term outcome data are now available
and presented in Table 1. Patients included in this study
were predominantly female (4/5), with a mean age of
7 years (range 6–12 years) at the time of transplant. The
mean disease duration before ASCT was 53 years (range
25–8 years). Patients had a variety of treatment
approaches before ASCT including corticosteroids, meth-
otrexate and biological agents although for several of
these patients ASCT was carried out at a time when bio-
logical agents were less available for JIA than they are
currently.
Conditioning regimens for ASCT included anti-T-cell
globulin, cyclophosphamide, prednisolone with fludara-
bine or total body irradiation in some cases (Table 1).
Four of the five patients achieved complete remission
after 10 or more years of follow up (mean 115, range
10–13 years), whereas one patient (patient 3) relapsed
shortly after transplant.
Frequency of peripheral blood cell subsets are highly
skewed early after ASCT
Peripheral blood mononuclear cells were isolated from
venous blood samples taken before transplant, shortly
after transplant (1 month), at intermediate follow up
(3–12 months) and late follow up (2–3 years) and
assessed for expression of leucocyte and NK cell markers
by flow cytometry (Fig. 1). In Fig. 1(a) representative
CD4 and CD8 staining on CD3+ T cells is shown;
Table 1. Clinical features and outcomes of patients studied
Patient Transplant year Age at transplant/gender Treatment before ASCT Conditioning regimen Long term follow up
1 2000 6/F S, M, CsA ATG 20, Cy 200, TBI, (P) CR 13 years
2 2000 10/M S, M, Ig ATG 40, Cy 200, (P) CR 13 years
3 2004 7/F S, M, CsA, TNF, IL-6 ATG 20, Cy 200, (P) Early relapse
4 2003 10/F S, M, Ig, TNF, IL-6 ATG 20, Cy 120, Flu 150, (P) CR 10 years
5 2003 12/F S, M, Ig, CsA, Cy ATG 20, Cy 100, Flu 150, (P) CR 10 years
ASCT, autologous stem cell transplantation; S, corticosteroids; M, methotrexate; CsA, cyclosporine A; Ig, intravenous immunoglobulin (high
dose, immunomodulatory); TNF, tumour necrosis factor-a inhibitors; IL-6, interleukin-6 receptor inhibitor; Cy, cyclophosphamide in mg/kg/total
dose; ATG, anti-T-cell globulin (rabbit) in mg/kg/total dose; TBI, total body irradiation (400 cGy); P, prednisolone; Flu, fludarabine in mg/kg/
total dose; CR, complete remission.
Some data adapted from Abinun et al.5
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apparent differences in staining intensities are the result
of technical differences in flow cytometer settings over
time, and not a biological effect. Immediately after
ASCT, mononuclear cell subsets were highly skewed
compared with cell numbers before transplant. Consider-
able decreases in CD3+ T-cell and CD19+ B-cell frequen-
cies were observed, while an increase in frequency of
CD14+ monocytes was seen (Fig. 1b). However, the
apparent increase in one cell subset reflects the decrease
in another subset, and actual counts in all cell subsets
during this period were low, as illustrated in the Sup-
porting information, Table S2 for one representative
patient. By 12 months post transplant, no significant dif-
ferences compared with before ASCT were observed in
frequency of T and B cells, monocytes, NK cells as
defined by CD16+ CD3 and NK-T cells as defined by
CD16+ CD3+; however, relative cell proportions were
still variable at this time-point.
To further investigate the immunological features asso-
ciated with remission from severe childhood arthritis,
expression of T-cell sub-population markers was exam-
ined at the same time-points as above. The CD4+ to
CD8+ T-cell ratio reversed immediately post stem cell
transplantation, and had recovered to the baseline ratio
by 2–3 years (Fig. 1c), indicating an early expansion of
CD8+ T cells relative to CD4+ T cells. In the CD8+ T-cell
population, relative frequency of CD45RA+ naive T cells
decreased while frequency of CD45RO+ memory T cells
increased, normalizing to baseline by 2–3 years post
transplant (Fig. 1d). A similar, but less striking, pattern
Figure 1. Highly skewed frequency of periph-
eral blood cell subsets early after autologous
stem cell transplantation (ASCT). Expression
of cell surface markers examined before and
after ASCT by flow cytometry. (a) Representa-
tive flow cytometry plots, showing CD4 (y-
axis) versus CD8 (x-axis) expression on cells
gated on live CD3+ T cells 1 month before and
1, 12 and 31 months after ASCT in patient 1.
Percentages of events in each gate are shown.
(b) Total T (CD3+, left) and B (CD19+, mid-
dle) cell and monocyte (CD14+, right) propor-
tions before ASCT and at 1 month,
3–12 months and 2–3 years after ASCT. All
gated on live cells according to forward and
side scatter, some using live–dead discrimina-
tion. (c) CD4+ (left) and CD8+ (middle) T-cell
proportions, gated on live CD3+ cells, and the
CD4/CD8 ratio (right). (d) Naive (CD45RA+,
left) and memory (CD45RO+, middle) T-cell
proportions, gated on live CD3+ CD8+ T cells.
Throughout, horizontal bars in summary plots
represent the mean, n = 2–5 (where samples
were available).
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of CD45RA and CD45RO expression was observed in the
CD4+ T-cell population (data not shown).
Oligoclonal TCR repertoire in CD8+ T-cell subset
early in immune reconstitution
To assess the reconstitution of the T-cell immune reper-
toire after immune depletion and stem cell infusion, the
clonality of the T-cell repertoire was studied before and
after ASCT by TCRVb CDR3 length spectratyping. Spec-
tratyping is a multiplex T-cell assay that can separate
TCRVb CDR3 by length, and can be a useful technique
to study overall TCR diversity.23,24 Where a large clonal
population is present, the amplification of the CDR3
region from this clone produces a ‘spike’ in the typically
Gaussian distribution of CDR3 amplification products.
At the same time-points as investigated above, TCRVb
CDR3 spectratyping from sorted CD4+ and CD4 T-cell
subsets was performed. The CD4-negative sorted fraction
was used as a source of CD8+ T-cell TCR mRNA analysis,
because other cells in this fraction (monocytes, B cells,
NK cells, cd T cells) do not express a TCR-ab, and NK-T
cells represent a very low percentage of cells.
The TCR diversity of three patients (patients 1, 2, 3)
was analysed in detail. In the CD4+ T-cell subset, the
TCRVb CDR3 distribution was normally diverse in all Vb
families before transplant. One month post ASCT, CDR3
length distribution was predominantly oligoclonal. By
12 months post ASCT, full CDR3 length diversity was
restored in all Vb families tested and with quality reads.
Data from one individual (patient 1), in whom ASCT led
to remission of severe arthritis, are shown in Fig. 2, with
five representative TCRVb.
We observed different patterns in the clonality of
TCRVb, when comparing diversity before, immediately
after, and at later time-points after ASCT. In Fig. 3,
TCRVb diversity of the CD4-negative T-cell subset (rep-
resenting CD8+ T cells) is shown for three patients before
and after transplant; patient 1 (Fig. 3a) and patient 2
(Fig. 3b) had successful ASCT, whereas patient 3 (Fig. 3c)
relapsed after ASCT. For patient 1, at baseline, in all Vb
families other than Vb15 and Vb21, TCRVb CDR3 distri-
bution was normally diverse (representative examples
shown in Fig. 3a, top). One month after transplant,
TCRVb CDR3 distribution was highly skewed in every Vb
family, suggesting that a highly oligoclonal T-cell reper-
toire was generated early in immune reconstitution.
Twelve months post transplant, full CDR3 length diversity
was re-established in five out of 24 families, namely
TCRVb Vb1, 5, 8, 17 and 23 (Fig. 3a, pattern A).
Increased T-cell clonal diversity in these instances might
suggest that de novo T-cell development and TCR rear-
rangement occurs after ASCT and this may contribute to
remission from autoimmune disease. In comparison,
however, CDR3 length distribution remained skewed at
12 months post transplant in 13 of 24 families (Vb2, 3, 4,
6a, 6b, 9, 11, 13a, 13b, 14, 15, 18 and 21). Of interest, in
some families, in addition to dominant peaks at different
lengths, a re-emergence of some dominant peaks from
pre-ASCT was observed (Fig. 3a, pattern B). This might
suggest that in certain instances, some T cells, bearing
specific TCRVb CDR3 expression, could persist through
immunosuppressive conditioning and have a proliferative
advantage over T-cell clones that are newly generated post
transplant.
TCRVb diversity analysis of the CD4-negative T-cell
subset (representing CD8+ T cells) in patient 2 (Fig. 3b)
showed similar patterns to patient 1. Some TCRVb
showed oligoclonal distribution before and later after
transplant (namely TCRVb 1, 4, 7, 16, 21, Fig. 3b, pattern
Figure 2. Highly oligoclonal CD4+ T-cell
receptor b variable region (TCRVb) repertoire
early in immune reconstitution in patient 1,
who obtained remission after autologous stem
cell transplantation (ASCT). TCRVb CDR3
length spectratyping for Vb1, Vb8 Vb4, Vb15
and Vb21; samples tested from before and 1
and 12 months after ASCT (top to bottom as
shown). Representative TCRVb CDR3 spectra-
types are shown from patient 1.
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A). Pattern B, re-emergence of dominant clones of partic-
ular CDR3 lengths, was also observed in patient 2
(Fig. 3b, pattern B, TCRVb3 11, 12, 13b and 15). To
investigate the relative frequency of TCRVb family usage
TCR family expression was analysed by flow cytometry.
No major change in TCRVb family usage was observed in
CD8+ T cells before and at later time-points after trans-
plant (see Supporting information, Fig. S1). However, we
observed skewing in TCRVb use early after transplant,
which correlated well with the oligoclonality seen in the
spectratyping analysis.
Spectratyping of TCR species from the CD8+ T-cell
population was also studied in the one child who relapsed
after ASCT. At baseline, TCRVb CDR3 distribution was
normally diverse in the majority of Vb families (represen-
tative examples shown in Fig. 3c, pattern C). However, in
striking contrast to the spectrayping pattern observed in
patient 1 and 2, full TCRVb CDR3 length diversity was
Figure 3. Highly oligoclonal CD8+ T-cell receptor b variable region (TCRVb) repertoire early in immune reconstitution in patients, who were in
remission after autologous stem cell transplantation (ASCT), (Patterns A and B) compared with high TCRVb diversity in the patient who
relapsed (Pattern C). Patient 1 (a) and patient 2 (b) TCRVb CDR3 length spectratyping for respective TCRVb falling into pattern A (left) and
pattern B (right); TCRVb as labelled; samples tested for patient 1: before and 1 and 12 months after ASCT and for patient 2: before and
235 months after ASCT. (c) TCRVb CDR3 length spectratyping in same Vb families before and 3 months after ASCT in patient 3 (pattern C).
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observed early after transplant in every Vb family tested
(Fig. 3c, pattern C). Of note, this child received cyclo-
phosphamide and anti-thymocyte globulin in standard
dose pre-transplant, compared with patient 2 who
received a higher dose of anti-thymocyte globulin, or
other patients who received another agent or treatment
(total body irradiation, fludarabine). It has been suggested
previously that the conditioning regimen with lower ATG
dose or no third agent, may not be sufficient for full
immunodepletion.5
A chimeric TCR repertoire, comprising clones from
before and after transplant, can be associated with
remission from severe arthritis
The TCR spectratyping data presented above suggested
that some T-cell clones might persist through immuno-
suppressive conditioning, surviving either in the patient
or possibly being transferred in the grafted stem cells
themselves, and expand after transplant. To further inves-
tigate this possibility, clonality of T cells was studied at
the level of TCR sequences. TCR sequencing analysis pro-
vides a semi-quantitative analysis of clonal frequency
within a population of T cells, can identify clones that
have expanded from a single T-cell clone, and may pro-
vide evidence for survival of specific T-cell clones, after
this treatment strategy.
Vb4, 15 and 21 family CD4 T-cell subset PCR prod-
ucts from patient 1, represented in Fig. 3, pattern B, and
who achieved complete remission from severe arthritis
after ASCT, were chosen for sub-cloning and TCR
sequencing. As predicted, in the Vb15 family, specific
TCR sequences that were identified from the sample
obtained before ASCT were also identified post-ASCT
(Table 2 and Fig. 4a). Interestingly, the relative clonal
sizes of re-emerging clones were comparable before, and
12 months after, ASCT (clone with N region sequence
GVGG 4% before and 48% after transplant, DYEN 48%
before and 81% after transplant). In contrast, in Vb4 and
Vb21 families, new dominant clones were identified
12 months after ASCT, with the clone with N region
sequence GTGE representing 54% of total sequences in
Vb4 and the clone with N region sequence HGTG repre-
senting 100% of Vb21 (Fig. 4b and c, respectively). Fur-
thermore, the dominant clones before transplant (Vb4:
clone with N region sequence RHIP 11%, Vb15: AAGA
48%) were not found post transplant (Fig. 4b and c,
respectively). However, because only between 16–24
clones were sequenced in these Vb families at each time-
point, overlapping clones could have been missed.
Discussion
Systemic juvenile idiopathic arthritis is the most severe
form of JIA and has the potential to be highly debilitating
or even fatal. Where therapies fail due to drug toxicity or
ineffectiveness, autologous stem cell transplantation is a
valuable treatment option. When successful, ASCT can
lead to full sustained remission; however, pre-transplant
immunosuppressive conditioning and parallel treatment
can have severe side effects with high mortality. To date
we do not understand how ASCT works or who is likely
Table 2. T-cell receptor b variable region (TCRVb) sequences across CDR3 region in patient 1
ND, not determined.
Sub-cloning of CDR3 of Vb15, Vb4 and Vb21 in CD4 T cell subset (representing CD8+ T cells) from patient 1. Variable region of the TCRb
chain (Vb), N region, joining region of the TCRb chain (Jb) and constant region of the TCRb chain (Cb) family classifications for clonal
sequences are shown. Number of sequences in each clone/total number of sequences (top) and size of clone as a percentage (bottom) are shown
before ASCT (pre), 1 month after ASCT (1/12 post) and 12 months after ASCT (12/12 post).
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to respond. It has been suggested that ASCT might reset
the immune system or give rise to a new immune reper-
toire.16
The data presented here suggest that, although cell sub-
sets are skewed and the T-cell repertoire is oligoclonal
early after ASCT, long-term alterations in frequency of
cell subsets and the generation of an entirely new T-cell
repertoire might not be necessary for remission from
severe arthritis. Remission from severe arthritis can be
associated with an immune system comprising T-cell
clones found before transplant as well as de novo gener-
ated T-cell clones. In addition, on the basis of data from
one patient who relapsed rapidly, it could be speculated
that full TCRVb CDR3 length diversity early after trans-
plant may be associated with relapse of arthritis after
ASCT, and could be indicative of unsatisfactory condi-
tioning.
It has been suggested that in MS, ASCT works through
the generation of a mainly de novo T-cell compartment
with higher diversity. However, in a study of seven adult
MS patients treated with CD34+ enriched autologous hae-
matopoietic stem cells, a small but detectable number of
pre-transplant clones were clearly picked up after trans-
plant. The re-emergence of peaks was also seen on spec-
tratyping in some TCRVb families.17 Furthermore, clones
reactive to known disease-associated antigens were found
post transplant in another study of ASCT in MS.19 Inter-
estingly these had decreased (pathological) T helper type
17 (Th17) responses, but equivalent Th1 responses com-
pared with cells isolated before transplant. The self-pro-
tein heat-shock protein 60 (hsp60) has been implicated in
regulating arthritis,25–27 and T cells from patients with
JIA after ASCT had increased interleukin-10 and Th2
responses with reduced Th1/interferon-c responses when
re-stimulated with hsp60-loaded antigen presenters.6
These results might suggest that induction of self-toler-
ance and remission from disease may be achieved
through the resetting of immune balance. In this study
we were not able to compare cytokine responses of T cells
before and after transplant. However, demonstrating the
re-emergence of pre-transplant T-cell receptor clones after
transplant in the context of remission enriches and cor-
roborates the evidence of the above studies, by showing
that the same clones re-emerge; compared with reactivity
to the same antigens described by the studies above.
Thus, these findings contribute towards our understand-
ing of the immunological basis of remission after ASCT.
In agreement with previous studies,17,20,21 we found
that relative frequencies of cell subsets were highly skewed
early after transplant, with a reversal of the CD4/CD8
T-cell ratio, low CD45RA and high CD45RO frequencies
among both CD4+ and CD8+ T cells. It is known that
early in immune reconstitution CD8+ T cells have prolif-
erative advantage over CD4+ T cells.28 In this study by
Mackal et al., this was due to proliferation of CD8+
T cells outside the thymus, probably from non-depleted
memory CD8+ T cells, whereas CD4+ T cells mainly
re-generated through thymic selection. Thymic reconstitu-
tion of the periphery takes time. It has been shown that
normal peripheral CD4+ T-cell numbers are typically
reached after approximately 1 year post transplant.10 This
may explain the reversal of CD4+ and CD8+ T cells early
after transplant.
This study could not investigate regulatory T-cell fre-
quencies, however, another study on JIA ASCT showed
that after transplant there is a rebound in the numbers of
Figure 4. Two patterns of T-cell receptor
(TCR) b repertoire: re-emergence of old and
establishment of new T-cell clones after autolo-
gous stem cell transplantation (ASCT). Sub-
cloning of the CDR3 of Vb15 (a), Vb4 (b) and
Vb21 (c) in CD4 T-cell subset (representing
CD8+ T cells). (a) Vb15 with N region protein
sequence: GVGG: white; DYEN: light grey;
RGNS: dark grey and DLGS: black stripes. (b)
Vb4 with N region protein sequence: RHIP:
white and GTGE: light grey. (c) Vb21 with N
region protein sequence: AAGA: white and
HGTG: light grey. Throughout, unique N
region sequences in black. 16–24 sequences per
Vb analysed.
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regulatory T cells.6 In an animal arthritis model of autol-
ogous bone marrow transplantation regulatory T cells
increased early after transplant and actively controlled
arthritis to a low level later after transplant.29
It has been speculated that immune depletion may
reset ‘immunological memory’. However, interestingly,
results of this study may suggest that although some
T-cell depletion is needed, complete T-cell depletion
might not be essential for remission and re-emergence of
dominant clones is a feature of successful ASCT. The
presence of identical N region (V-D-J) nucleotide
sequences of individual TCR clones found at varying time
points, as we have demonstrated here, is a strong indica-
tor that these are cells from the same clone, i.e that such
clones have in fact persisted (in vivo or in transplanted
material) from before transplant to post transplant.
Patient 3 relapsed early after transplant and showed
polyclonal TCRVb spectra, potentially indicating that the
conditioning dose may have been unsatisfactory.5 It could
be speculated that full TCRVb CDR3 length diversity seen
early after transplant in patient 3 might be associated
with the failure of ASCT as treatment. However, this is
only one patient and further investigations would be nec-
essary to confirm this. Other limitations of this study
include the low number of sequences analysed for TCRVb
sequencing, meaning that further reoccurring but low-fre-
quency clones might have been missed. However, even in
a small sequence pool, as analysed here, the overlap of
pre- and post-transplant clonality strongly indicates reoc-
currence of T-cell clones post transplant as a real phe-
nomenon in ASCT. A larger sample size for each time-
point with phenotyping and TCR diversity analysis would
have been desirable; however, available samples and
patients undergoing ASCT were limited.
It is important to note that all patients in this study
were treated at a time when disease-modifying anti-rheu-
matic drugs such as methotrexate were the mainstay of
treatment but before many of the biological agents were
available. The management of this disease has changed
considerably since the advent of these novel biological
agents in recent years, such as Tocilizumab (humanized
anti-interleukin-6 receptor antibody) and Anakinra
(interleukin-1 receptor antagonist) or other interleukin-
1b blockade agents. With the introduction of more effec-
tive biological agents, ASCT is likely to become a later
treatment step in JIA. However, there are many uncer-
tainties about the success of ASCT after intense immuno-
suppressive effects associated with long-term use of
powerful novel biological agents. At present, it is unclear
at what time-point and for which children ASCT may be
a valuable and appropriate treatment. Therefore, submis-
sion of outcomes to the national (UK) and European
blood and marrow transplant database (http://www.ebmt.
org) may be a vital contribution in informing future
management decisions.
Understanding mechanisms underlying disease and
treatment is important, to achieve the future goal to suc-
cessfully treat patients with JIA and other autoimmune
conditions, both through ASCT and other immunomodu-
latory methods. There is a need for treatments with fewer
adverse events and minimal drug toxicity. Further
research is needed to help define patients most suited for
ASCT, and it may help to determine optimal condition-
ing regimens for induction of remission, while minimiz-
ing risks associated with intense immunosuppressive
therapy. The results presented here indicate that develop-
ment of an entirely new immune system with complete
re-generation of de novo T cells might not be necessary
for remission from severe arthritis. Indeed, it appears that
a chimeric TCR repertoire, comprising clones generated
before and after transplant, can be associated with long-
term remission from severe arthritis.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Primer sequences.
Table S2. Absolute cell counts for patient 1.
Figure S1. T-cell receptor b variable region (TCRVb)
expression before and after autologous stem cell trans-
plantation (ASCT). Frequency of expression of 24 TCRVb
families was assessed using flow cytometry before (top
left), and 1 month (top centre), 19 months (top right),
235 months (bottom left) and 375 months (bottom cen-
tre) after transplant in the CD8+ T-cell subset in patient
2. Gated on live CD8+ T cells and then each TCRVb pop-
ulation. Pie charts show relative proportion of Frequency
of total cells positive for each TCRVb shown (in grey-
scale), with other (in white) representing frequency of
CD8+ T cells not accounted for by any of the 24 TCRVb
families investigated.
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